BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, July 9, 2025
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

BioWorld and Nasdaq stock indices

Nov. 3, 2023
These graphs compare the performance of the biotech stocks for all of 2023 using the BioWorld Stock Indicator and the Nasdaq Biotech Index.
Read More

Biopharma money raised: Jan. 1-Nov. 2, 2023

Nov. 3, 2023
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Biopharma money raised by quarter in 2023 (US$M)

Nov. 3, 2023
Biopharma money raised to-date and by month in 2023, including public, private and other financings.
Read More

Money raised by biopharma

Nov. 3, 2023

Total raised in public, private and other financings of biopharma companies, comparing 2019-2023.


Read More
Stock chart, red down arrow
Med-tech financings October 2023

Up from September low, med-tech financings down nearly 42% for the year

Nov. 3, 2023
By Amanda Lanier
Med-tech saw some good news in October, with total financings value reaching $1.22 billion, an increase of 89.23% from the $645.75 million in September. However, the increase didn’t make up for the broader year-over-year decline in med-tech investments.
Read More
Businesswoman pressing dollar sign on touchscreen
Biopharma financings October 2023

Biopharma financings reach $11.6B in October, highest month since 2021

Nov. 3, 2023
By Amanda Lanier
In October, the biopharma industry secured $11.6 billion in financings, marking the highest monthly amount since June 2021 when value totaled $12.3 billion. Biopharma financings have averaged $6.1 billion per month so far in 2023, an increase from the $5.07 billion monthly average for all of 2022.
Read More
Cancer cell
BioWorld Cancer Index (BCI)

BCI flourishes despite widespread stock declines

Nov. 1, 2023
By Amanda Lanier
The BioWorld Cancer Index (BCI) saw its highest point of the year from April through July, when it had a run above 30%, before falling to 23.5% at the end of August. It closed Q3 up 22.96% for the year, a sharp divergence from the more extensive Nasdaq Biotechnology Index and Dow Jones Industrial Average, which are tracking down 6.16% and up 1.09%, respectively.
Read More
Test tubes, capsules, dropper
Biopharma clinical updates September 2023

Clinical trial data show 1.79% growth year-on-year through Q3 2023

Oct. 31, 2023
By Amanda Lanier
Clinical trial data from January-September 2023 was up 1.79% compared to the same time period last year. In the first three quarters of this year, BioWorld reported on 2,611 drugs in phase I-III, compared to 2,565 in Q1-Q3 2022. The number of trial updates is down 13.74% from 3,027 in 2021 and also down from the 2,738 in 2020, but up from 2,251 updates noted in 2019.
Read More

Med-tech gainers and losers for Oct. 23-27, 2023

Oct. 30, 2023
The top 10 med-tech stock gainers and losers for the week.
Read More

Biggest gainers and losers for Oct. 23-27, 2023

Oct. 30, 2023
The top 10 biopharma stock gainers and losers for the week.
Read More
Previous 1 2 … 85 86 87 88 89 90 91 92 93 … 267 268 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 8, 2025.
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • Kidney disease illustration

    Prokidney produces positive phase II CKD data, thunderous stock surge

    BioWorld
    A mixed bag of top-line phase II data prompted stellar stock results for Prokidney Corp. and its chronic kidney disease (CKD) and diabetes therapy, rilparencel....
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing